Portal de Periódicos da CAPES

Latent forms of TGF‐β: Molecular Structure and Mechanisms of Activation

2007; Wiley; Linguagem: Inglês

10.1002/9780470514061.ch6

1935-4657

Kohei Miyazono, Carl‐Henrik Heldin,

Protease and Inhibitor Mechanisms

TGF-β proteins are produced as latent, high molecular weight complexes. The latent form of TGF-β1 (L-TGF-β1) in human platelets comprises three components: the mature TGF-β1 molecule, the N-terminal remnant of the TGF-β1 precursor in dimeric form and a novel component denoted TGF-β1-binding protein (TGF-β1-BP). Recombinant TGF-β1 expressed in CHO cells, which lacks TGF-β1-BP, is also produced as a latent form. Thus, the N-terminal remnant of the TGF-β1 precursor is sufficient for TGF-β1 latency, and it was denoted TGF-β1 latency-associated peptide (TGF-β1-LAP). The cDNA for TGF-β1-BP has been cloned. It is mainly composed of two different kinds of repeat sequences, i.e. 16 epidermal growth factor-like repeats and three copies of a cysteine-rich repeat hitherto not found in other proteins. The function of TGF-β1-BP remains to be elucidated. Activation of L-TGF-β can be achieved by different chemical and enzymic treatments, or by incubation with certain cell types. Understanding of the physiological activation mechanisms and the in vivo roles of L-TGF-β will be important for future clinical applications of TGF-β.